[1]
|
T. J. Barber, A. Hughes, W. W. Dinsmore and A. Phillips, “How Does HIV Impact on Non-AIDS Events in the Era of HAART?” International Journal of STD AIDS, Vol. 20, No. 1, 2009, pp. 1-3. doi:10.1258/ijsa.2008.008302
|
[2]
|
M. A. Hacker, A. Kaida, R. S. Hogg and F. I. Bastos, “The First Ten Years: Achievements and Challenges of the Brazilian Program of Universal Access to HIV/AIDS Comprehensive Management and Care, 1996-2006,” Cadernos de Saúde Pública, Vol. 23, No. S3, 2007, pp. S345-S359.
|
[3]
|
D. Ogoina et al., “Morbidity and Mortality Patterns of Hospitalised Adult HIV/AIDS Patients in the Era of Highly Active Antiretroviral Therapy: A 4-Year Retrospective Review from Zaria, Northern Nigeria,” AIDS Research and Treatment, Vol. 2012, No. 2012, 2012, Article ID: 940580.
|
[4]
|
O. Keiser et al., “Adverse Events to Antiretrovirals in the Swiss HIV Cohort Study: Effect on Mortality and Treatment Modification,” Antiviral Therapy, Vol. 12, No. 8, 2007, pp. 1157-1164.
|
[5]
|
R. J. Zinn, C. Serrurier, S. Takuva, I. Sanne and C. N. Menezes, “HIV-Associated Lipodystrophy in South Africa: The Impact on the Patient and the Impact on the Plastic Surgeon,” Journal of Plastic, Reconstructive & Aesthetic Surgery, Vol. 66, No. 6, 2013, pp. 839-844.
doi:10.1016/j.bjps.2013.02.032
|
[6]
|
J. M. Llibre et al., “The Changing Face of HIV/AIDS in Treated Patients,” Current HIV Research, Vol. 7, No. 4, 2009, pp. 365-377. doi:10.2174/157016209788680633
|
[7]
|
S. Emamzadeh-Fard, S. E. Fard, S. Seyed Alinaghi and K. Paydary, “Adherence to Anti-Retroviral Therapy and Its Determinants in HIV/AIDS Patients: A Review,” Infectious Disorders Drug Targets, Vol. 12, No. 5, 2012, pp. 346-356. doi:10.2174/187152612804142251
|
[8]
|
S. Bautista-Arredondo, T. Dmytraczenko, G. Kombe and S. M. Bertozzi, “Costing of Scaling up HIV/AIDS Treatment in Mexico,” Salud Pública de México, Vol. 50, No. S4, 2008, pp. S437-S444.
|
[9]
|
S. Apanga, D. Punguyire and G. Adjei, “Estimating the Cost to Rural Ambulating HIV/AIDS Patients on Highly Active Antiretroviral Therapy (HAART) in Rural Ghana: A Pilot Study,” The Pan African Medical Journal, Vol. 12, No. 2012, 2012, p. 21.
|
[10]
|
E. Naik et al., “Cost of Treatment: The Single Biggest Obstacle to HIV/AIDS Treatment Adherence in Lower-Middle Class Patients in Mumbai, India,” Indian Journal of Sexually Transmitted Diseases, Vol. 30, No. 1, 2009, pp. 23-27. doi:10.4103/0253-7184.55476
|
[11]
|
M. Fantoni et al., “Symptom Profile in Terminally Ill AIDS Patients,” AIDS Patient Care and STDs, Vol. 10, No. 3, 1996, pp. 171-173. doi:10.1089/apc.1996.10.171
|
[12]
|
M. J. Hommes et al., “Increased Resting Energy Expenditure in Human Immunodeficiency Virus-Infected Men,” Metabolism, Vol. 39, No. 11, 1990, pp. 1186-1190.
doi:10.1016/0026-0495(90)90092-Q
|
[13]
|
J. C. Melchior et al., “Resting Energy Expenditure in Human Immunodeficiency Virus-Infected Patients: Comparison between Patients with and without Secondary Infections,” The American Journal of Clinical Nutrition, Vol. 57, No. 5, 1993, pp. 614-619.
|
[14]
|
J. C. Melchior et al., “Resting Energy Expenditure Is Increased in Stable, Malnourished HIV-Infected Patients,” The American Journal of Clinical Nutrition, Vol. 53, No. 2, 1991, pp. 437-441.
|
[15]
|
M. J. Batterham, “Investigating Heterogeneity in Studies of Resting Energy Expenditure in Persons with HIV/ AIDS: A Meta-Analysis,” The American Journal of Clinical Nutrition, Vol. 81, No. 3, 2005, pp. 702-713.
|
[16]
|
World Health Organization, “Nutrient Requirements for People Living with HIV/AIDS: Report of a Technical Consultation,” 2003.
|
[17]
|
C. R. Loonam and A. Mullen, “Nutrition and the HIV-Associated Lipodystrophy Syndrome,” Nutrition Research Reviews, Vol. 25, No. 2, 2012, pp. 267-287.
doi:10.1017/S0954422411000138
|
[18]
|
W. W. Fawzi et al., “A Randomized Trial of Multivitamin Supplements and HIV Disease Progression and Mortality,” The New England Journal of Medicine, Vol. 351, No. 1, 2004, pp. 23-32. doi:10.1056/NEJMoa040541
|
[19]
|
S. Jiamton et al., “A Randomized Trial of the Impact of Multiple Micronutrient Supplementation on Mortality among HIV-Infected Individuals Living in Bangkok,” AIDS, Vol. 17, No. 17, 2003, pp. 2461-2469.
doi:10.1097/00002030-200311210-00008
|
[20]
|
J. D. Kaiser et al., “Micronutrient Supplementation Increases CD4 Count in HIV-Infected Individuals on Highly Active Antiretroviral Therapy: A Prospective, Double-Blinded, Placebo-Controlled Trial,” Journal of Acquired Immune Deficiency Syndromes, Vol. 42, No. 5, 2006, pp. 523-528. doi:10.1097/01.qai.0000230529.25083.42
|
[21]
|
K. Kawai et al., “A Randomized Trial to Determine the Optimal Dosage of Multivitamin Supplements to Reduce Adverse Pregnancy Outcomes among HIV-Infected Women in Tanzania,” The American Journal of Clinical Nutrition, Vol. 91, No. 2, 2010, pp. 391-397.
doi:10.3945/ajcn.2009.28483
|
[22]
|
R. D. Semba et al., “Micronutrient Supplements and Mortality of HIV-Infected Adults with Pulmonary TB: A Controlled Clinical Trial,” The International Journal of Tuberculosis and Lung Disease, Vol. 11, No. 8, 2007, pp. 854-859.
|
[23]
|
J. E. Forrester and K. A. Sztam, “Micronutrients in HIV/ AIDS: Is There Evidence to Change the WHO 2003 Recommendations?” The American Journal of Clinical Nutrition, Vol. 94, No. 6, 2011, pp. 1683S-1689S.
doi:10.3945/ajcn.111.011999
|
[24]
|
N. Siegfried, J. H. Irlam, M. E. Visser and N. N. Rollins, “Micronutrient Supplementation in Pregnant Women with HIV Infection,” Cochrane Database of Systematic Reviews, Vol. 3, No. 2012, 2012, Article ID: CD009755.
|
[25]
|
E. E. Lutge, A. Gray and N. Siegfried, “The Medical Use of Cannabis for Reducing Morbidity and Mortality in Patients with HIV/AIDS,” Cochrane Database of Systematic Reviews, Vol. 4, No. 2013, Article ID: CD005175.
|
[26]
|
X. Kong, G. Wu and Y. Yin, “Roles of Phytochemicals in Amino Acid Nutrition,” Frontiers in Bioscience (Scholar Edition), Vol. 3, No. 2011, 2011, pp. 372-384.
|
[27]
|
B. Holst and G. Williamson, “Nutrients and Phytochemicals: From Bioavailability to Bioefficacy beyond Antioxidants,” Current Opinion in Biotechnology, Vol. 19, No. 2, 2008, pp. 73-82. doi:10.1016/j.copbio.2008.03.003
|
[28]
|
X. Wang et al., “Phytochemicals and Biological Studies of Plants from the Genus Balanophora,” Chemistry Central Journal, Vol. 6, No. 1, 2012, p. 79.
doi:10.1186/1752-153X-6-79
|
[29]
|
L. Z. Sun, N. L. Currier and S. C. Miller, “The American Coneflower: A Prophylactic Role Involving Nonspecific Immunity,” Journal of Alternative and Complementary Medicine, Vol. 5, No. 5, 1999, pp. 437-446.
doi:10.1089/acm.1999.5.437
|
[30]
|
B. B. Aggarwal and S. Shishodia, “Suppression of the Nuclear Factor-KappaB Activation Pathway by Spice-Derived Phytochemicals: Reasoning for Seasoning,” Annals of the New York Academy of Sciences, Vol. 1030, No. 2004, 2004, pp. 434-441.
|
[31]
|
E. G. de Mejia and M. V. Ramirez-Mares, “Ardisia: Health-Promoting Properties and Toxicity of Phytochemicals and Extracts,” Toxicology Mechanisms and Methods, Vol. 21, No. 9, 2011, pp. 667-674.
doi:10.3109/15376516.2011.601355
|
[32]
|
B. N. Rao, “Bioactive Phytochemicals in Indian Foods and Their Potential in Health Promotion and Disease Prevention,” Asia Pacific Journal of Clinical Nutrition, Vol. 12, No. 1, 2003, pp. 9-22.
|
[33]
|
D. O. Kennedy and E. L. Wightman, “Herbal Extracts and Phytochemicals: Plant Secondary Metabolites and the Enhancement of Human Brain Function,” Advances in Nutrition, Vol. 2, No. 1, 2011, pp. 32-50.
doi:10.3945/an.110.000117
|
[34]
|
G. P. Kumar and F. Khanum, “Neuroprotective Potential of Phytochemicals,” Pharmacognosy Reviews, Vol. 6, No. 12, 2012, pp. 81-90.
|
[35]
|
M. H. Traka and R. F. Mithen, “Plant Science and Human Nutrition: Challenges in Assessing Health-Promoting Properties of Phytochemicals,” Plant Cell, Vol. 23, No. 7, 2011, pp. 2483-2497. doi:10.1105/tpc.111.087916
|
[36]
|
S. Rajaram, “The Effect of Vegetarian Diet, Plant Foods, and Phytochemicals on Hemostasis and Thrombosis,” The American Journal of Clinical Nutrition, Vol. 78, No. S3, 2003, pp. 552S-558S.
|
[37]
|
G. Bagalkotkar, S. R. Sagineedu, M. S. Saad and J. Stanslas, “Phytochemicals from Phyllanthus Niruri Linn and Their Pharmacological Properties: A Review,” Journal of Pharmacy and Pharmacology, Vol. 58, No. 12, 2006, pp. 1559-1570. doi:10.1211/jpp.58.12.0001
|
[38]
|
A. Imaz, V. Falco and E. Ribera, “Antiretroviral Salvage Therapy for Multiclass Drug-Resistant HIV-1-Infected Patients: From Clinical Trials to Daily Clinical Practice,” AIDS Reviews, Vol. 13, No. 3, 2011, pp. 180-193.
|
[39]
|
J. F. Senise, A. Castelo and M. Martinez, “Current Treatment Strategies, Complications and Considerations for the Use of HIV Antiretroviral Therapy during Pregnancy,” AIDS Reviews, Vol. 13, No. 4, 2011, pp. 198-213.
|
[40]
|
C. A. Shah, “Adherence to High Activity Antiretrovial Therapy (HAART) in Pediatric Patients Infected with HIV: Issues and Interventions,” Indian Journal of Pediatrics, Vol. 74, No. 1, 2007, pp. 55-60.
doi:10.1007/s12098-007-0028-8
|
[41]
|
R. Subbaraman, S. K. Chaguturu, K. H. Mayer, T. P. Flanigan and N. Kumarasamy, “Adverse Effects of Highly Active Antiretroviral Therapy in Developing Countries,” Clinical Infectious Diseases, Vol. 45, No. 8, 2007, pp. 1093-1101. doi:10.1086/521150
|
[42]
|
O. R. Obiako and H. M. Muktar, “Challenges of HIV Treatment in Resource-Poor Countries: A Review,” Nigerian Medical Journal, Vol. 19, No. 4, 2010, pp. 361-368. doi:10.4314/njm.v19i4.69785
|